Pulmovant Advances Mosliciguat Into Phase 3 After Positive PHocus Data
WALTHAM, Massachusetts — September 8, 2026 Pulmovant announced positive topline results from the Phase 2 PHocus study of mosliciguat...
Pulmonary Disease
Advertisement
Draeger Receives FDA Clearance for Evita V800 Upgrade
TELFORD, Pennsylvania, June 22, 2026 Draeger, Inc., the U.S. headquarters of global medical technology leader Dräger, has announced that...
Atisama Advances RB042 Phase 1 Trial and Strengthens Leadership
Melbourne, Australia – May 15, 2026 Atisama Therapeutics, formerly known as Rage Bio, announced significant progress in the ongoing...
Transpire Bio Gains FDA Acceptance for High-Strength Generic Trelegy
SUNRISE, Fla., May 11, 2026 Transpire Bio Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted...
Advertisement
